The global antiepileptic drugs market is anticipated to grow at a considerable CAGR of 2.6% during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, Therachon Holding AG, a privately owned clinical-stage biotechnology business, has been acquired by pfizer Inc.
Browse the full report description of “Global Antiepileptic Drugs Market Size, Share & Trends Analysis Report by Drug Type (First Generation AEDs- Phenytoin (Dilantin, Phenytek), Carbamazepine (Carbatrol), Oxycarbazepine (Trileptal), Valproate (Depakote & Others) & (Second Generation AEDs- Lamotrigine (Lamictal), Pregabalin (Lyrica), Rufinamide (Banzel/Inovelon), Levetiracetam (Keppra) & Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/antiepileptic-drugs-market
Therachon Holding AG is a privately held clinical-stage biotechnology company. Pfizer Inc. paid an additional USD 470 million for Therachon Holding AG, in addition to $340 million, under the terms of the acquisition. Following the fulfilment of major milestones in the marketing and development of TA-46, a further payment of USD 470 million was made. In September 2019, GW Pharmaceuticals plc. launches the new innovations drugs, EPIDYOLEX that are used for the Dravet syndrome or Lennox Gastaut syndrome as an adjunction the therapy of seizures.
In addition, in May 2021, Epilepsy Foundation, a U.S. based non-profit national foundation entered into a collaboration with Eisai Inc. is a Japanese pharmaceutical company that developed the Epilepsy Digital Experience Navigator platform designed to empower people with epilepsy. The caregiver and clinician use data to better improvement of the epilepsy journey. Further, in November 2019, SK Biopharmaceuticals, Co., Ltd., a global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) has approved XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adults. With the approval of XCOPRI, clinicians will have a new treatment option for patients who are still having focal (partial-onset) seizures. The approval is based on the findings of two global, randomised, double-blind, placebo-controlled studies, as well as a major, global, multi-center, open-label safety study that involved adults with uncontrolled partial-onset seizures who were using one to three anti-epileptic drugs concurrently (AEDs).
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Type
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Antiepileptic Drugs Market Report Segment
By Drug Type
First Generation AEDs
Second Generation AEDs
Global Antiepileptic Drugs Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/antiepileptic-drugs-market